KURA实时信号 | 通过Getagraph.com最大化利润

购买 105613 min ago

@ $19.65

发出时间: 15 Feb 2024 @ 04:45

回报率: 0.00%

上一信号: Feb 14 - 22:30

上一信号: 出售

回报率: -2.04 %

Live Chart Being Loaded With Signals

Commentary (27 Apr 2024 @ 04:00):

Stats
今日成交量	543 365
平均成交量	1.14M
市值	1.50B
EPS	$0 ( 2024-02-27 )
下一个收益日期	( $-0.560 ) 2024-05-08
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-9.45
ATR14	$0.0160 (0.08%)

Insider Trading

Date	Person	Action	Amount	type
2024-01-29	Doyle Thomas James	Sell	594	Common Stock
2024-01-29	Doyle Thomas James	Sell	761	Common Stock
2024-01-29	Doyle Thomas James	Sell	963	Common Stock
2024-01-29	Bair Teresa Brophy	Sell	2 053	Common Stock
2024-01-29	Ford Kathleen	Sell	1 496	Common Stock

INSIDER POWER
42.13
Last 95 transactions
Buy: 6 371 376 \| Sell: 2 723 562

音量相关性

長: 0.46 (neutral)

短: -0.82 (strong negative)

Signal:(62.055) Neutral

Kura Oncology Inc 相关性

10 最正相关
RMRM	0.943
GAINL	0.888
LQDT	0.876
TRVN	0.857
SLNH	0.85
QTEK	0.834
SWVL	0.825
HYMC	0.824
VYNT	0.817
LITM	0.808

10 最负相关
FANH	-0.844

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Kura Oncology Inc 相关性 - 货币/商品

0.16
( neutral )

0.24
( neutral )

0.00
( neutral )

0.28
( neutral )

0.13
( neutral )

-0.37
( neutral )

Kura Oncology Inc 财务报表

Annual	2023
营收:	$0
毛利润:	$-849 000 (0.00 %)
EPS:	$-2.08

FY	2023
营收:	$0
毛利润:	$-849 000 (0.00 %)
EPS:	$-2.08

FY	2022
营收:	$0
毛利润:	$-759 000 (0.00 %)
EPS:	$-2.03

FY	2021
营收:	$0.00
毛利润:	$0.00 (0.00 %)
EPS:	$-1.970

Financial Reports:

No articles found.

Kura Oncology Inc

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A protein-protein interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; and tipifarnib, an orally bioavailable inhibitor of farnesyl transferase that is in Phase II clinical trials for the treatment of solid tumors and hematologic indications. The company has a clinical collaboration with Novartis to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression or PIK3CA mutation and/or amplification. Kura Oncology, Inc. was founded in 2014 and is headquartered in San Diego, California.